InvestorsHub Logo
Followers 800
Posts 50849
Boards Moderated 1
Alias Born 12/12/2004

Re: HoldEm777 post# 1776

Wednesday, 03/16/2022 8:26:48 PM

Wednesday, March 16, 2022 8:26:48 PM

Post# of 2847
In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Sonnet BioTherapeutics Holdings (SONN – Research Report), with a price target of $2.50. The company's shares closed last Wednesday at $0.52, close to its 52-week low of $0.26. According to TipRanks.com, Nakae is a 4-star analyst with an average return of 10.9% and a 41.9% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Mountain Crest Acquisition II, Arrowhead Pharmaceuticals, and Emergent Biosolutions. Sonnet BioTherapeutics Holdings has an analyst consensus of Strong Buy, with a price target consensus of $2.17, representing a 338.4% upside. In a report issued on March 10, H.C.
https://www.tipranks.com/news/blurbs/chardan-capital-thinks-sonnet-biotherapeutics-holdings-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral

New York Yankees and Duke Basketball

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SONN News